Business Context and Reporting Period
This Form 8-K, dated April 3, 2026, reports the completion of a strategic transaction by Ginkgo Bioworks Holdings, Inc. (the "Company"). On this date, the Company finalized the sale of its Biosecurity segment, operated through its subsidiary Ginkgo Biosecurity, LLC ("Biosecurity"), to Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.).
Key Financial Metrics and Transaction Terms
The filing details the consideration received for the disposition of assets but does not provide specific revenue, profit, cash flow, or debt figures for the Company's remaining operations within this text.
- Transaction Consideration: The Company received shares of common stock of the Purchaser representing approximately 20% of the Purchaser's issued and outstanding equity on a fully diluted basis.
- Assets Transferred: All issued and outstanding equity interests of Biosecurity, constituting substantially all operations of the Company's Biosecurity segment.
- Accounting Treatment: The transaction meets the criteria for Discontinued Operations under ASC 205-20.
- Pro Forma Data: Unaudited pro forma financial statements are filed as Exhibit 99.1, reflecting the transaction as if it occurred on January 1, 2023, and a balance sheet as of December 31, 2025. Specific numerical values for these statements are not included in the filing text provided.
Material Changes Versus Prior Period
The primary material change is the divestiture of the Biosecurity segment. This transaction fundamentally alters the Company's operational scope, removing the Biosecurity segment from future consolidated results. The filing does not provide comparative financial metrics (e.g., revenue or net income) for the prior period to quantify the financial impact of this removal in this specific text.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard legal disclaimers regarding the Purchase Agreement. The transaction is described as previously announced, with the full terms detailed in the Stock Purchase Agreement filed on February 27, 2026.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma Condensed Consolidated Balance Sheet and Statements of Operations to understand the financial impact of the divestiture.
- Examine the Stock Purchase Agreement (filed as Exhibit 1.1 to the February 27, 2026 8-K) for detailed terms, conditions, and representations.
- Verify the valuation and liquidity of the 20% equity stake received in Tower Biosecurity, Inc.
- Confirm the classification of the Biosecurity segment as discontinued operations in future quarterly and annual reports.